- $82.42m
- -$42.54m
- 24
- 49
- 52
- 35
Annual income statement for Adicet Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 17.9 | 9.73 | 25 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 57.1 | 71.2 | 97.5 | 152 | 128 |
| Operating Profit | -39.2 | -61.4 | -72.6 | -152 | -128 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -39.5 | -62.1 | -69.8 | -143 | -117 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -36.7 | -62 | -69.8 | -143 | -117 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -36.7 | -62 | -69.8 | -143 | -117 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -36.7 | -62 | -69.8 | -143 | -117 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -5.01 | -1.98 | -1.7 | -2.86 | -1.33 |